Vinblastine
- Generic Name
- Vinblastine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H58N4O9
- CAS Number
- 865-21-4
- Unique Ingredient Identifier
- 5V9KLZ54CY
- Background
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
- Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
- Associated Conditions
- Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
- Associated Therapies
- -
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT00352027
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
HD11 for Intermediate Stages
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1395
- Registration Number
- NCT00264953
HD10 for Early Stages
- Conditions
- Interventions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1370
- Registration Number
- NCT00265018
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT00225173
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT00215046
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2009-09-07
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 60
- Registration Number
- NCT00147875
- Locations
- 🇩🇪
University of Cologne, Cologne, NRW, Germany
SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease
- Conditions
- Interventions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 348
- Registration Number
- NCT00002495
- Locations
- 🇺🇸
CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
🇺🇸CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 104
- Registration Number
- NCT00086801
- Locations
- 🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Beebe Medical Center, Lewes, Delaware, United States
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT00003084
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
- Conditions
- First Posted Date
- 2004-04-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 330
- Registration Number
- NCT00003376
- Locations
- 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.